Roche Holding AG

23 oct. 2024, 05:38 UTC

Roche Increases Dividend on Higher Sales

30 sept. 2024, 05:44 UTC

Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for Upfront $850 Million

12 sept. 2024, 09:29 UTC

Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects

7 août 2024, 07:03 UTC

Roche Weighs Divestment of Cancer Data Startup, FT Reports

5 août 2024, 22:43 UTC

Poseida Rises After Reporting Smaller-Than-Seen Loss, Partnership Progress

29 oct. 2024, 21:31 UTC

AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com

23 oct. 2024, 08:57 UTC

Roche's Pharma Growth Drivers Deliver -- Market Talk

23 oct. 2024, 08:10 UTC

Roche's Backed Outlook Could Drive Consensus Downgrades on Adverse Currency Effects -- Market Talk

23 oct. 2024, 07:02 UTC

Roche Posts Solid Results On Better-Than-Expected Key Drugs Performance -- Market Talk

23 oct. 2024, 05:03 UTC

Roche 3Q Sales Rose 9%

23 oct. 2024, 05:02 UTC

Roche to Further Increase Dividend

23 oct. 2024, 05:01 UTC

Roche Had Seen 2024 Sales Growth In Mid-Single-Digits

23 oct. 2024, 05:01 UTC

Roche Had Seen Core EPS Growth In High Single-Digits

23 oct. 2024, 05:01 UTC

Roche Backs 2024 View

23 oct. 2024, 05:01 UTC

Roche 9-Mos Sales CHF44.98B

1 oct. 2024, 14:47 UTC

Lonza Announced Acquisition on March 20

1 oct. 2024, 14:46 UTC

Lonza Has Bought Manufacturing Site in California From Roche for $1.2B

1 oct. 2024, 14:45 UTC

Lonza Completes Acquisition of Biologics Site in Vacaville (US) From Roche

1 oct. 2024, 09:54 UTC

Roche's Pharma Strategy Reflects Confident Pipeline Outlook -- Market Talk

1 oct. 2024, 07:04 UTC

Roche's Pharma Strategy Signals Obesity Push -- Market Talk

1 oct. 2024, 06:06 UTC

Roche's Sharpened R&D Focus, Cost Discipline Should Clear Productivity Concerns -- Market Talk

30 sept. 2024, 11:21 UTC

Roche's Giredestrant Gains Combination Potential With Regor's CDK Inhibitor Deal -- Market Talk

30 sept. 2024, 05:29 UTC

Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for Upfront $850 Mln

30 sept. 2024, 05:16 UTC

Regor: Sale Expected to Close 4Q, Subject to Conditions

30 sept. 2024, 05:15 UTC

Regor Also Eligible to Get More Cash Payments Based on Certain Milestones

30 sept. 2024, 05:15 UTC

Regor to Get $850 Mln Upfront Payment From Sale

30 sept. 2024, 05:14 UTC

Regor to Sell Portfolio of Breast Cancer Treatment CDK Inhibitors to Roche

30 sept. 2024, 05:14 UTC

Regor Selling Inhibitors to Roche Unit Genentech

19 août 2024, 20:01 UTC

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

7 août 2024, 14:22 UTC

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ